DUBLIN, Calif., Sept. 8 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced that Michael Molkentin, Chief Financial Officer, and Michael V. McCullar, Ph.D., Vice President of Drug Discovery Operations, are scheduled to co-present at the Merriman 5th Annual Investor Summit on Monday, September 15, 2008 at the Mark Hopkins Hotel in San Francisco.
SuperGen's presentation at the Merriman Investor Summit is scheduled to begin at 8:30 a.m. PDT (11:30 a.m. EDT). A live webcast of the presentation will be available on the investor relations section of the Company's Web site at http://www.supergen.com. A webcast replay of the presentation will be available shortly following the live event.
Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company
dedicated to the discovery and development of novel cancer therapies.
SuperGen is developing a number of therapeutic anticancer products focused
on kinase and cell signaling inhibitors and DNA methyltransferase
inhibitors. For more information about SuperGen, please visit
Timothy L. Enns
SVP, Corporate Communications
& Business Development
Tel: (925) 560-0100
Mary M. Vegh
Manager, Investor Relations
Tel: (925) 560-2845
Dorland Global Public Relations
Michael Beckerich (Media)
Tel: (212) 677-7632
|SOURCE SuperGen, Inc.|
Copyright©2008 PR Newswire.
All rights reserved